Investor Alert

Market Pulse Archives

Sept. 10, 2021, 8:01 a.m. EDT

Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Apellis Pharmaceuticals Inc. (APLS)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Apellis Pharmaceuticals Inc. /zigman2/quotes/202103251/composite APLS -4.84% plunged 31.6% toward a 10-month low to pace all premarket losers Friday, after one of the Phase 3 studies of the biopharmaceutical company's eye disease treatment failed to meet its primary endpoint. The company said late Thursday that the OAKS study for pegcetacoplan met the primary endpoint, as it significantly reduced geographic atrophy (GA) lesion growth, while the DERBY study missed its primary endpoint of GA lesion growth reduction. The company said it plans to submit a New Drug Application (NDA) for pegcetacoplan for GA to the U.S. Food and Drug Administration in the first half of 2022. Wedbush downgraded Apellis to neutral from outperform, saying the previous upgraded was predicated on both studies holding a "high probability of success," but the readout ended up in the "mixed bag" scenario. J.P. Morgan slashed its stock price target to $57 from $101, but kept its overweight rating, saying "patience required" but pegcetacoplan "likely gets across the goal line" eventually. Apellis' stock has shed 2.8% year to date through Thursday, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB -2.19% has advanced 14.8% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.11% has gained 19.6%.

US : U.S.: Nasdaq
$ 52.29
-2.66 -4.84%
Volume: 1.16M
Feb. 8, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$6.08 billion
Rev. per Employee
US : U.S.: Nasdaq
$ 133.33
-2.99 -2.19%
Volume: 1.37M
Feb. 8, 2023 4:00p
-46.14 -1.11%
Volume: 0.00
Feb. 8, 2023 4:53p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.